Russian researchers developed a complex gene therapy drug

23 August 2018

GMP News

Russian researchers have developed a complex antitumor gene therapy drug. They have already carried out preclinical testing of cancer drug called AntionkoRAN-M.

Two genes (a cell killer and an immunostimulatory molecule) are enclosed in a polymer shell which plays role of a drug delivery vehicle. Experts believe that such innovative drug will stand for the future of oncology, since it does not have as many side effects as chemotherapy or radiotherapy.

Dr. Marina Sekacheva, head of the Center for Personalized Oncology “OncoTarget” at the First Moscow State Medical University (Sechenov University) hopes for an earliest opportunity to use the new Russian drug in practice.

“Unfortunately, great success of modern Oncology research does not cover all malignant tumors. Head and neck cancer are difficult to treat; they are characterized by aggressive tumor cells growth, a high degree of patients’ disability. The possibilities of surgical treatment are limited by the specific area where tumor cells start growing. Therefore, development of each new drug will be met with great enthusiasm by oncologists. So, now we will wait for clinical trials to be completed taking in account successful first preclinical results,” commented Dr. Sekacheva.

Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more